Dissolution testing is a standardized laboratory technique used to measure the rate and extent at which an active pharmaceutical ingredient (API) is released from a dosage form and dissolves into a specified liquid medium. For pharmaceutical and biotechnology companies, this testing provides valuable information about product performance, formulation behavior, manufacturing consistency, and potential bioavailability.
Although dissolution testing is particularly important for oral solid dosage forms, such as tablets and capsules, it can also be adapted for suspensions, modified-release products, transdermal systems, and other dosage forms. By evaluating drug release under carefully controlled conditions, scientists can compare formulations, establish specifications, investigate manufacturing changes, and monitor product quality throughout its lifecycle.
Dissolution data may be used by formulation scientists, analytical development teams, quality control personnel, regulatory affairs professionals, manufacturing teams, and other stakeholders. Regulatory agencies also review dissolution data as part of certain drug applications and submission supporting post-approval strategies.
BA Sciences (BA) provides dissolution testing as part of our comprehensive analytical testing capabilities, including method development, validation, method transfer, stability testing, and routine testing. With experience supporting pharmaceutical development since 1987, BA Sciences can develop customized dissolution programs or perform testing according to applicable compendial methods, including USP <711> Dissolution Testing.
Why Dissolution Testing Matters
A dissolution test places a drug product into a controlled volume of dissolution medium under specified conditions. An appropriate apparatus creates defined hydrodynamic conditions, and samples are collected at predetermined intervals. Analytical techniques are then used to quantify how much API has entered solution. The resulting data provide a measurable drug release profile.
A test may evaluate the percentage of drug dissolved at a single specified time or measure multiple timepoints to construct a complete dissolution profile. Dissolution testing should also be distinguished from the broader concept of a release assay. A release assay may measure API content, potency, purity, or another characteristic to determine whether a finished batch satisfies an established specification. Dissolution specifically evaluates how the drug is released and dissolves under defined conditions and can itself be an important component of finished-product release testing.
The Role of Dissolution Testing in Drug Development
Dissolution testing can begin early in formulation development. Scientists can compare prototypes to determine how differences in excipients, particle size, coatings, manufacturing parameters, or dosage form design influence drug release. These studies can help development teams identify formulations that provide the desired release behavior before committing resources to later-stage development.
Dissolution may also provide information related to potential bioavailability. For an orally administered product, the API generally must be available in solution before it can cross gastrointestinal membranes and enter systemic circulation. Dissolution data may help predict absorption-related performance, but only within the limits of the product and model. Slow or incomplete dissolution may therefore limit absorption for some compounds.
However, an in vitro dissolution result is not automatically equivalent to in vivo bioavailability. Drug permeability, gastrointestinal transit, food effects, metabolism, and other biological variables can also influence systemic exposure.
For generic drug developers, dissolution testing can be especially important during Abbreviated New Drug Application (ANDA) development. Under the FDA’s biopharmaceutics classification system framework, BCS-based biowaivers can allow in vitro dissolution data to replace in vivo bioequivalence studies for suitable products and support stronger in vitro-in vivo correlations. Comparative dissolution profiles may help demonstrate similarity between a proposed generic drug and its reference listed drug, support formulation decisions, and contribute to a broader bioequivalence strategy.
Dissolution Method Development
An effective dissolution method should be scientifically appropriate for the dosage form, control the critical variables, and remain capable of consistently measuring meaningful differences in product performance. One important objective is discriminatory power. A discriminating method should detect changes that could affect product performance without being so sensitive that analytically insignificant variations create misleading results.
Media and test conditions should be selected based on API properties and formulation behavior, and the dissolution procedure should be set up under standardized conditions. Depending on the purpose of the study, development scientists may use compendial media, buffers at different pH values, or biorelevant media designed to better represent gastrointestinal environments.
Sampling intervals should provide enough information to characterize release kinetics and the drug release rate. An immediate-release formulation may require relatively early sampling points, while an extended-release product may require measurements over many hours.
Analytical endpoints are equally important. UV spectroscopy and high-performance liquid chromatography (HPLC) are commonly used to quantify dissolved API by tracking concentration as a function of time, with the appropriate technique determined by sensitivity, selectivity, formulation complexity, and the concentrations being measured.
Dissolution Method Validation
Before a dissolution method becomes part of routine testing or a regulatory control strategy, its suitability should be demonstrated and documented to ensure it is fit for purpose. Validation considerations may include specificity or selectivity, accuracy, precision, linearity, range, robustness, and other performance characteristics appropriate to the method’s intended purpose.
System suitability procedures should verify that the analytical measurement system is performing acceptably. Precision studies help demonstrate that the method can produce consistent results under defined conditions.
Robustness testing evaluates whether small, deliberate changes to method parameters materially affect the result. Depending on the method, variables could include pH, medium composition, agitation rate, temperature, filtration conditions, or analytical parameters.
Acceptance criteria should be scientifically justified before validation begins. Clearly defined criteria reduce ambiguity and make it easier to determine whether a method is suitable for its intended application. Validation failures often arise from poorly defined acceptance criteria or inadequate discriminatory power. Current analytical procedure development and validation strategies should also consider ICH Q14, ICH Q2(R2), and ICH Q2(R1) guidance, which frame analytical procedure development and validation within a lifecycle approach. Strong validation also supports method transfer and helps prevent method drift between sites.
Dissolution Apparatus and Methods
Under USP General Chapter 711 dissolution, the following standardized apparatus are commonly used for compendial testing:
USP Apparatus I – Basket: The dosage form is placed in a rotating basket submerged in dissolution medium. It is frequently used for capsules and dosage forms that may otherwise float.
- USP Apparatus II – Paddle: A paddle rotates above the dosage form in the dissolution vessel. This is the most widely used method for immediate-release tablets.
- USP Apparatus III – Reciprocating Cylinder: The dosage form moves through media using reciprocating motion. This apparatus can be useful for modified-release products and studies involving sequential media.
- USP Apparatus IV – Flow-Through Cell: Dissolution medium flows through a cell containing the dosage form. The system provides flexibility for products requiring controlled flow conditions or specialized release testing.
- Other USP apparatus include Apparatus V – Paddle Over Disk, Apparatus VI – Reciprocating Cylinder/Holder systems, and Apparatus VII – Reciprocating Holder, which may be appropriate for specialized dosage forms and release applications.
Apparatus suitability is also essential. For USP Apparatus I and II, Performance Verification Testing (PVT) provides evidence that the complete dissolution assembly is functioning appropriately. Mechanical qualification and applicable performance verification procedures should be incorporated into a laboratory’s equipment qualification and maintenance program.
Dissolution Specifications
Dissolution specifications establish the acceptance criteria used to evaluate product performance. A specification should be based on development data, formulation characteristics, clinical or bioavailability information when applicable, manufacturing capability, stability data, compendial requirements, and regulatory expectations.
There is no single dissolution percentage and timepoint that applies universally to all drug products. Acceptance criteria must reflect the specific product and method. Depending on the application, specifications may use a single timepoint or multiple timepoints. Modified-release products commonly require more extensive profiles because both premature release and insufficient later release may be important performance considerations.
Statistical approaches can also be used when comparing complete dissolution profiles. For example, similarity factor approaches may be appropriate in certain comparative dissolution evaluations when their underlying conditions and regulatory requirements are satisfied.
For regulatory submissions, dissolution documentation may include the method, development rationale, validation information, specifications, representative data, comparative profiles, analytical procedures, and information supporting the proposed Chemistry, Manufacturing, and Controls (CMC) strategy.
Dissolution Testing for Different Dosage Forms
Different dosage forms require different testing strategies.
Tablets
USP Apparatus II, or the paddle method, is commonly used for tablets because it provides controlled agitation while allowing the dosage form to disintegrate and dissolve within the vessel. Apparatus I may be selected when formulation characteristics make a basket system more appropriate.
Capsules
Capsules may float or behave inconsistently when first introduced into dissolution medium. USP Apparatus I is commonly used for capsules, while sinkers may be appropriate with paddle methods when justified by the procedure. Method development should also determine whether the capsule shell or retention system interferes with release.
Suspensions
Suspensions present different analytical challenges because sample homogeneity becomes important. A representative sampling plan should account for settling, mixing, withdrawal location, and sample preparation. The method must distinguish true dissolution behavior from variability introduced through inconsistent sample handling.
Dissolution Strategies for Challenging APIs
Poorly soluble APIs and complex formulations can require more sophisticated development strategies. For low-solubility compounds, researchers may investigate pH, ionic strength, surfactants, or other scientifically justified medium modifications. The goal is to obtain meaningful release information without creating conditions that conceal important formulation differences.
pH-shift experiments can provide additional insight into compounds that encounter significantly different environments as they move from the stomach into the intestine. Sequential testing may help characterize precipitation, supersaturation, or changes in dissolution rate.
Micro-dissolution techniques can be valuable during early development when API quantities are limited. Smaller-scale studies allow formulation scientists to obtain preliminary dissolution information while conserving material.
Advanced analytical platforms, including sensitive chromatographic and mass spectrometric techniques, may also be useful when dissolved API concentrations are extremely low or when degradation products, excipients, and related substances complicate quantitation.
Dissolution Tests as Quality Control and Stability Tools
Once a method and specification have been established, dissolution can become an important quality control tool. Routine batch-release testing is performed under the validated procedure to verify that manufactured lots continue to meet defined drug release requirements and ensure continued conformance. The sampling schedule is established by the validated or compendial procedure rather than by a universal testing frequency.
Dissolution testing may also be incorporated into stability programs at selected timepoints. Comparing results over time can reveal formulation aging, coating changes, altered disintegration behavior, or other changes that affect release.
Trending is especially valuable. Even when individual batches remain within specification, gradual shifts in dissolution profiles can provide information about manufacturing processes, raw materials, storage conditions, or product aging. Changes in the manufacturing process can have an impact on dissolution profiles over time and should be monitored during trend reviews. Reviewing trends as part of an ongoing pharmaceutical quality system can help identify potential issues before they become specification failures.
BA Sciences Services: Laboratory and Analytical Support
Effective dissolution programs require more than access to an instrument. Method selection, analytical development, validation, equipment suitability, sample handling, documentation, stability planning, and regulatory requirements must work together to generate reliable data.
BA Sciences supports pharmaceutical and biotechnology organizations across these stages. Our analytical development capabilities include dissolution method development alongside HPLC, UPLC, ICP-MS, GC, particle size analysis, ion chromatography, and mass spectrometry. BA Sciences can develop new methods, evaluate existing procedures, optimize complex methods, perform feasibility studies, validate analytical procedures, troubleshoot analytical issues, and support method transfer.
For ongoing programs, BA Sciences also provides analytical testing for CMC parameters, product characterization, in-process and lot release testing, and cGMP stability and storage services. Stability programs can include long-term and accelerated studies, photostability testing, thermal cycling, monitored storage, data collection, and reporting to support regulatory filings.
BA Sciences operates as a cGMP-compliant, FDA/DEA-registered, ISO/IEC 17025:2017-certified analytical testing laboratory serving pharmaceutical, biotechnology, medical device, and other life science organizations.
Whether you need to establish a new dissolution method, validate or transfer an existing procedure, investigate a challenging formulation, conduct routine release testing, or incorporate dissolution into a stability program, BA Sciences can develop an analytical approach around your product and regulatory requirements. Contact us today.